Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK MHRA to facilitate availability of medicines database throughout EU

This article was originally published in SRA

Executive Summary

The UK’s Medicines and Healthcare products Regulatory Agency has introduced a system that allows it to automatically transfer data from its medicines database (Sentinel information management system) onto EudraGMP, the European database designed to facilitate exchange of information on compliance with good manufacturing practice1.

You may also be interested in...



OTC Drug Firms' Online Subscription Sales Would Jeopardize Retail Partnerships

OTC drug firms would cannibalize their sales at retailers if they offer online subscription sales, the rapidly growing e-commerce model that offers advantages that appeal to consumers, says former P&G marketing executive Brent Walker.

OTC Drug Firms' Online Subscription Sales Would Jeopardize Retail Partnerships

OTC drug firms would cannibalize their sales at retailers if they offer online subscription sales, the rapidly growing e-commerce model that offers advantages that appeal to consumers, says former P&G marketing executive Brent Walker.

First Oral Treatment For Spinal Muscular Atrophy Gets EMA Nod

New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel